|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Oligospermia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Totally, we observed seven oligozoospermia associated variants (rs3791185 and rs2232015 in PRMT6, rs146039840 and rs11046992 in Sox5, rs1129332 in PEX10, rs3197744 in SIRPA, rs1048055 in SIRPG) in the first stage.
|
24303009 |
2013 |
|
Bulbo-Spinal Atrophy, X-Linked
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The enhanced interaction of PRMT6 and mutant AR leads to neurodegeneration in cell and fly models of SBMA.
|
25569348 |
2015 |
|
Azoospermia, Nonobstructive
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A previous Chinese genome-wide single-nucleotide polymorphism (SNP) association studies have identified four SNPs (rs12097821 in PRMT6 gene, rs2477686 in PEX10 gene, rs6080550 in SIRPA-SIRPG, and rs10842262 in SOX5 gene) as being significantly associated with risk factors for nonobstructive azoospermia (NOA).
|
30863997 |
2019 |
|
Non-obstructive azoospermia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The combined analyses identified significant (P < 5.0 × 10(-8)) associations between NOA risk and common variants near PRMT6 (rs12097821 at 1p13.3: odds ratio (OR) = 1.25, P = 5.7 × 10(-10)), PEX10 (rs2477686 at 1p36.32: OR = 1.39, P = 5.7 × 10(-12)) and SOX5 (rs10842262 at 12p12.1: OR = 1.23, P = 2.3 × 10(-9)).
|
22197933 |
2011 |
|
Cocaine Dependence
|
0.310 |
Biomarker
|
disease |
CTD_human |
Taken together, these findings suggest that suppression of Src signaling in NAc D2-MSNs, via PRMT6 and H3R2me2a down-regulation, functions as a homeostatic brake to restrain cocaine action, and provide novel candidates for the development of treatments for cocaine addiction.
|
27506785 |
2016 |
|
Cocaine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone arginine methylation in cocaine action in the nucleus accumbens.
|
27506785 |
2016 |
|
Cocaine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Histone arginine methylation in cocaine action in the nucleus accumbens.
|
27506785 |
2016 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
PELP1 and PRMT6 are co-recruited to estrogen receptor target genes, PELP1 knockdown affects the enrichment of histone H3R2 di-methylation, and PELP1 and PRMT6 coordinate to regulate the alternative splicing of genes involved in cancer.
|
24447537 |
2014 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
We conclude that PRMT6 acts as an oncogene in breast cancer cells, promoting growth and preventing senescence, making it an attractive target for cancer therapy.
|
22987071 |
2012 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.
|
30332648 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Our results indicate that PRMT6 appears to be one of the key proteins to dysregulate p21 functions in human cancer, and targeting this pathway may be an appropriate strategy for development of anticancer drugs.
|
26436589 |
2015 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Upregulated PRMT6 was found in various human diseases including cancer.
|
29927001 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.
|
30332648 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
PELP1 and PRMT6 are co-recruited to estrogen receptor target genes, PELP1 knockdown affects the enrichment of histone H3R2 di-methylation, and PELP1 and PRMT6 coordinate to regulate the alternative splicing of genes involved in cancer.
|
24447537 |
2014 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Upregulated PRMT6 was found in various human diseases including cancer.
|
29927001 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
We conclude that PRMT6 acts as an oncogene in breast cancer cells, promoting growth and preventing senescence, making it an attractive target for cancer therapy.
|
22987071 |
2012 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
Our results indicate that PRMT6 appears to be one of the key proteins to dysregulate p21 functions in human cancer, and targeting this pathway may be an appropriate strategy for development of anticancer drugs.
|
26436589 |
2015 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we investigate the molecular mechanism by which protein arginine methyltransferase 6 (PRMT6) exerts anti-invasiveness effect against breast cancer cells and prostate cancer cells.
|
23380452 |
2013 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that dysregulation of PRMT6-dependent transcription and alternative splicing may be involved in breast cancer pathophysiology and the molecular consequences identifying a unique and informative biomarker profile.
|
22673335 |
2012 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
PRMT6 knock-down (KD) results in a p21 derepression in breast cancer cells, which is p53-independent, and leads to cell cycle arrest, cellular senescence and reduced growth in soft agar assays and in severe combined immunodeficiency (SCID) mice for all the cancer lines examined.
|
22987071 |
2012 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that PELP1 oncogenic functions involve alternative splicing leading to the activation of unique pathways that support tumor progression and that the PELP1-PRMT6 axis may be a potential target for breast cancer therapy.
|
24447537 |
2014 |